Evidence map›Paper›PMID 40679816›Full record

ArticleJAMA health forum2025

Practice-Level Spending Variation for Radiation Treatment Episodes Among Older Adults With Cancer.

Miranda B Lam, Mary Beth Landrum, J Michael McWilliams, Benjamin Buzzee, Alexi A Wright, Nancy L Keating, Bruce E Landon

Abstract read
In one paragraph

Article in JAMA health forum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Miranda B LamDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
Mary Beth LandrumDepartment of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
J Michael McWilliamsDepartment of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
Benjamin BuzzeeDepartment of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
Alexi A WrightDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Nancy L KeatingDepartment of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
Bruce E LandonDepartment of Health Care Policy, Harvard Medical School, Boston, Massachusetts.

Funding

Assessing Variation in Outcomes for Cancer Patients Receiving Radiation Treatments and Identifying High-Value Radiation Oncology PracticesK08CA273549 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Miranda Lam · 2023 to 2026
$1.1M
NCI NIH HHS K08 CA273549
6 · The paper itself

Abstract

Importance: Radiation treatments are an essential but expensive component of cancer care. Objective: To elucidate trends in radiation spending and identify factors associated with practice-level variations across the US health care system to inform alternative payment model design. Design, Setting, and Participants: This population-based cross-sectional study analyzed fee-for-service Medicare beneficiaries from 2009 to 2020. Patients were continuously enrolled in fee-for-service Medicare Parts A and B during the 1 year prior through 28 days after a radiation treatment episode. Data were analyzed from January 2023 to September 2024. Exposures: Medicare beneficiaries with cancer who received radiation therapy. Main Outcomes and Measures: Radiation treatment-specific standardized spending and utilization during 90-day treatment episodes were examined and characterized by radiation type (conformal, intensity modulated, stereotactic, proton, or brachytherapy) and number of fractions. Linear regression models with practice random effects to understand practice-level variation in standardized radiation spending were estimated. Variables were added to adjust for year, patient demographics, cancer type, geography, radiation technology, and number of fractions per episode. Results: From 2009 to 2020, 1 898 864 beneficiaries with cancer (mean [SD] age, 74 [8.4] years; 48.5% female) initiated 2 149 385 radiation treatment episodes at 2150 practices. Mean (SD) 90-day standardized radiation treatment-specific spending was $13 683 ($8628). Practice-level per-episode radiation-specific spending variation was high (SD after adjusting for year, $4121). It remained high even after adjusting for patient demographic characteristics, cancer type, geography, radiation technology, and number of fractions (SD, $1487). From 2009 to 2020, unadjusted per-episode standardized radiation-specific spending increased slightly from $12 978 to $13 689 (P = .04). During this time, the median (IQR) number of fractions per episode decreased from 25 (10-33) to 16 (5-29) (P < .001), while the proportion of radiation episodes using intensity-modulated or proton radiation treatment increased (from 5% to 18% and 0.4% to 2%, respectively [both P < .001]) and use of conformal radiation treatment decreased from 61% to 38% (P < .001). Conclusions and Relevance: In this cross-sectional study, there was substantial variation in practice-level radiation spending and number of fractions for older patients with cancer undergoing radiation treatment both within and across health care markets. This practice-level variation suggests that there may be opportunities for savings under population-based payment models.

Indexed as

Health ExpendituresNeoplasmsRadiotherapyAgedAged, 80 and overCross-Sectional StudiesFee-for-Service PlansFemaleHumansMaleMedicareUnited States

Identifiers

PMID40679816
PMCPMC12274980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.